<DOC>
	<DOCNO>NCT01546987</DOCNO>
	<brief_summary>RATIONALE : Androgens cause growth prostate cancer cell . Drugs , steroid 17alpha-monooxygenase TAK-700 , use hormone therapy , may lessen amount androgen make body . Radiation therapy use high energy x ray kill tumor cell . This may effective treatment prostate cancer combine hormone therapy . Studying quality-of-life patient cancer treatment may help identify intermediate- long-term effect treatment patient prostate cancer . PURPOSE : This randomized phase III trial study use hormone therapy , include TAK-700 , together radiation therapy treat patient prostate cancer .</brief_summary>
	<brief_title>Hormone Therapy , Radiation Therapy , Steroid 17alpha-monooxygenase TAK-700 Treating Patients With High-Risk Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate difference overall survival patient clinically localized prostate cancer unfavorable prognostic feature ) standard treatment ( androgen-deprivation therapy [ ADT ] + radiotherapy ) b ) standard treatment addition 24 month steroid 17alpha-monooxygenase TAK-700 ( TAK-700 ) . Secondary - To characterize difference treatment group respect incidence unexpected grade ≥ 3 adverse event and/or clinically significant decrement patient-reported quality life ( QOL ) among subject treat TAK-700 . - To compare rate cumulative incidence biochemical control ( freedom PSA failure ) , local/regional progression , distant metastasis . - To compare rate cumulative incidence clinical failure , define prostate-specific antigen ( PSA ) &gt; 25 ng/mL , document local disease progression , regional distant metastasis , initiation ADT . - To compare prostate cancer-specific survival other-cause mortality . - To compare change severity fatigue measure Patient-Reported Outcome Measurement Information System ( PROMIS ) fatigue short form . - To compare change patient-reported QOL measure Expanded Prostate Cancer Index Composite ( EPIC ) . - To assess quality-adjusted survival use EQ-5D . - To compare nadir average serum testosterone 12 24 month treatment . - To compare change hemoglobin A1C , fast glucose , fast insulin 24 month systemic treatment first three year follow-up . - To compare change fast lipid level 24 month treatment first three year follow-up . - To compare change body mass index ( BMI ) 24 month treatment first three year follow-up . - To compare incidence adverse event ascertain via CTCAE version 4 . - To compare rate recovery testosterone &gt; 230 ng/dL ( accepted threshold supplementation ) 12 24 month follow-up . - To compare median time recovery testosterone &gt; 230 ng/dL first five year follow-up . - To assess cumulative incidence relevant clinical survivorship endpoint include new diagnosis type 2 diabetes , coronary artery disease , myocardial infarction , stroke , pulmonary embolism , deep vein thrombosis , osteoporotic fracture . OUTLINE : This multicenter , randomize study . Patients stratify accord risk group ( see Disease Characteristics ) type radiation therapy ( RT ) boost ( intensity-modulated RT ( IMRT ) v brachytherapy ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive standard androgen suppression ( AS ) luteinizing hormone-releasing hormone ( LHRH ) agonist ( leuprolide , goserelin , buserelin , triptorelin ) 24 month initiation oral ( PO ) antiandrogen ( flutamide bicalutamide ) begin 2 month prior duration radiation therapy ( RT ) . - Arm II : Patients receive standard AS LHRH agonist oral antiandrogen arm 1 . Patients also receive steroid 17alpha-monooxygenase TAK-700 ( TAK-700 ) PO twice daily ( BID ) 2 year . In arm , patient undergo IMRT 3D-conformal RT whole pelvis daily , 5 day week , 6-8 week . Some patient also receive brachytherapy . Quality life assess via Patient-Reported Outcome Measurement Information System ( PROMIS ) Fatigue Scale , Expanded Prostate Cancer Index Composite ( EPIC-26 ) , EuroQol ( EQ-5D ) assessments baseline periodically study . Serum may collect patient correlative study . After completion study therapy , patient follow every 3 month 2 year , every 6 month 1 year , annually thereafter .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Buserelin</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Flutamide</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Deslorelin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis adenocarcinoma prostate within 180 day prior registration high risk recurrence determine one follow combination ( risk group ) : Gleason Score ( GS ) ≥ 9 , PSA ≤ 150 ng/mL , T stage GS ≥ 8 , PSA &lt; 20 ng/mL , T stage ≥ T2 GS ≥ 8 , PSA ≥ 20150 ng/mL , T stage GS ≥ 7 , PSA ≥ 20150 ng/mL , T stage Baseline serum PSA value perform FDAapproved assay ( e.g. , Abbott , Hybritech ) , obtain prior luteinizing hormonereleasing hormone ( LHRH ) agonist antiandrogen therapy , within 180 day randomization Androgen deprivation therapy ( ADT ) , LHRH agonists ( e.g. , goserelin , leuprolide ) , antiandrogens ( e.g. , flutamide , bicalutamide ) , estrogens ( e.g. , diethyl stilbestrol [ DES ] ) , surgical castration ( orchiectomy ) , may start prior registration , provide registration within 50 day begin ADT ; please note : patient start ADT eligible participate quality life component study Clinically negative lymph node establish image ( abdominal and/or pelvic CT abdominal and/or pelvic MRI ) , nodal sampling , dissection within 90 day prior registration Patients lymph nodes equivocal questionable image eligible node &lt; 2.0 cm No distant metastasis ( M0 ) bone scan within 90 day prior registration Equivocal bone scan finding allow plain film negative metastasis No definite evidence metastatic disease Any patient undergo brachytherapy must transrectal ultrasound confirmation prostate volume &lt; 60 cc , American Urological Association ( AUA ) score ≤ 15 within 60 day registration , history prior transurethral resection prostate ( TURP ) Prior TURP permit patient receive externalbeam radiotherapy ( EBRT ) PATIENT CHARACTERISTICS : Height , weight , Zubrod performance status 01 Absolute neutrophil count ( ANC ) ≥ 1,800 cells/mm^3 Platelets ≥ 100,000 cells/mm^3 Hemoglobin ≥ 8.0 g/dL ( The use transfusion intervention achieve Hgb ≥ 8.0 g/dL acceptable ) Serum creatinine &lt; 2.0 mg/dL Creatinine clearance &gt; 40 mL/minute Bilirubin &lt; 1.5 x upper limit normal ( ULN ) Alanine aminotranserase ( ALT ) aspartate aminotransferase ( AST ) &lt; 2.5 x ULN No PSA &gt; 150 ng/mL Screening calculate ejection fraction ≥ ULN multiplegated acquisition ( MUGA ) scan echocardiogram Androgen deprivation therapy ( ADT ) , LHRH agonists ( e.g. , goserelin , leuprolide ) , antiandrogens ( e.g. , flutamide , bicalutamide ) , estrogens ( e.g. , DES ) , surgical castration ( orchiectomy ) may start prior registration , provide registration within 50 day begin ADT . Patients , even surgically sterilize ( i.e. , status post vasectomy ) , must agree practice effective barrier contraception entire study treatment period 4 month ( 120 day ) last dose study drug No prior invasive malignancy ( except nonmelanoma skin cancer ) unless diseasefree require systemic therapy minimum 3 year No know hypersensitivity TAK700 relate compound No history adrenal insufficiency No history myocardial infarction , unstable symptomatic ischemic heart disease , ongoing arrhythmia grade &gt; 2 ( NCI CTCAE , version 4.02 ) thromboembolic event ( e.g. , deep vein thrombosis , pulmonary embolism , symptomatic cerebrovascular event ) , cardiac condition ( e.g. , pericardial effusion restrictive cardiomyopathy ) within 6 month prior registration Chronic stable atrial fibrillation stable anticoagulant therapy allow No New York Heart Association Class III IV heart failure No ECG abnormality Qwave infarction , unless identify 6 month prior screen , correct QT ( QTc ) interval &gt; 460 msec No prior allergic reaction drug involve protocol No Cushing syndrome No severe chronic renal disease chronic liver disease No uncontrolled hypertension despite appropriate medical therapy within 21 day prior registration ( blood pressure great 150 mm Hg systolic 90 mm Hg diastolic 2 separate measurement 60 minute apart screen visit ) No serious infection within 14 day prior registration No uncontrolled nausea , vomit , diarrhea ( CTCAE grade ≥ 3 ) despite appropriate medical therapy time registration No know gastrointestinal ( GI ) disease GI procedure could interfere oral absorption tolerance TAK700 , include difficulty swallow tablet PRIOR CONCURRENT THERAPY : See Disease Characteristics Prior testosterone administration allow last administered least 90 day prior registration No prior radical prostatectomy , cryosurgery prostate cancer , bilateral orchiectomy reason No prior systemic chemotherapy prostate cancer Prior chemotherapy different cancer allow No prior radiotherapy , include brachytherapy , region prostate would result overlap radiation therapy field No previous hormonal therapy &gt; 50 day No chronic treatment glucocorticoid within one year No major surgery within 14 day prior registration No investigational agent No anticancer therapy No concurrent hormonal therapy include estrogen herbal product No concurrent ketoconazole aminoglutethimide No chronic use systemic corticosteroid , oral prednisone</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>